Advantis Corp., has acquired a 25% stake in US-based pain management and physical therapy company Sequence Therapy , LLC, which sees an exponential growth in revenue, from the current $0.5m a year, with the addition of the app-based revenue.

The acquisition will help Advantis to provide license-based digital application technology and achieve long-lasting results in the treatment of chronic pain.

Madrigal Pharmaceuticals , Inc. has announced a definitive agreement to merge with Synta Pharmaceuticals Corp.

The all-stock transaction will result in the merger of Madrigal with Synta’s wholly-owned subsidiary Saffron Merger Sub, Inc.

The merged entity will focus on developing small-molecule drugs to meet major unmet needs in cardiovascular-metabolic diseases and non-alcoholic steatohepatitis.